Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Which has preferable valuation & earnings, CPRX or ASND?

Catalyst Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$491.73M	5.41	$163.89M	$1.57	13.89
Ascendis Pharma A/S	$368.70M	29.01	-$409.12M	-$6.28	-27.86

Is CPRX or ASND more profitable?

Catalyst Pharmaceuticals has a net margin of 36.91% compared to Ascendis Pharma A/S's net margin of -93.22%. Catalyst Pharmaceuticals' return on equity of 42.45% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	36.91%	42.45%	36.59%
Ascendis Pharma A/S	-93.22%	N/A	-33.29%

Do institutionals and insiders hold more shares of CPRX or ASND?

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend CPRX or ASND?

Catalyst Pharmaceuticals presently has a consensus target price of $32.83, suggesting a potential upside of 50.54%. Ascendis Pharma A/S has a consensus target price of $223.07, suggesting a potential upside of 27.50%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Catalyst Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor CPRX or ASND?

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 8 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.40 beat Ascendis Pharma A/S's score of 0.81 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, CPRX or ASND?

Catalyst Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Ascendis Pharma A/S on 13 of the 17 factors compared between the two stocks.